Intrinsiqq
Summit Therapeutics Inc. logo

Summit Therapeutics Inc. Quality Score

SMMT

⊜ Compare
Quality10

Weak across most dimensions. This doesn't mean avoid, but the burden of proof is on the bull case.

Broad-market heuristics · Not a buy/sell signal

Valuation and growth

Earnings Multiple
0/100
-14.4x

Negative earnings, no valuation support

Cash Flow Multiple
0/100
-27.8x

Negative FCF, no valuation support

Cash Flow Growth
0/100
Negative FCF

FCF negative, burning cash after capex

Business Quality & Capital Allocation

Share Dilution
0/100
743.7%

Heavy dilution above 5%

Capital Structure
100/100
-$670M

Net cash position, no leverage concern

2021
$72.0M
$3.00M
2022
$349M
$24.0M
2023
$186M
$6.00M
2024
$412M
$7.00M
TTM
$691M
$20.0M
CashDebt
Return on Capital
0/100
-74.4%

Below 8%, may not cover cost of capital

Customize WeightsPremiumUpgrade

Summit Therapeutics (SMMT) quality: score, margins and returns

Summit Therapeutics (SMMT) scores 10/100 on Intrinsiqq's quality score (a lower-quality business), a weighted blend of 4 metrics each scored 0 to 100. Every metric is computed from SEC filings; this is analysis, not investment advice.

Frequently asked

Is Summit Therapeutics (SMMT) a high-quality business?+

Summit Therapeutics scores 10 out of 100 on Intrinsiqq's quality score, a weighted blend of 4 metrics each scored 0 to 100, which rates it a lower-quality business on these measures. Quality and price are separate questions: even a great business can be a poor investment if you overpay, so read this score alongside the valuation. The metric-by-metric breakdown is on this scorecard.

What does Summit Therapeutics's quality score measure?+

Intrinsiqq's quality score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, change in share count, and balance-sheet strength, each computed from SMMT's SEC filings rather than opinion or sentiment. A higher score means a more durable, capital-efficient business; it is not a buy or sell signal. Open each metric on this page to see exactly where Summit Therapeutics scores well and where it falls behind.

How the market compares: US profitability statistics

SourceQuality score computed from the 10-Q filed 17 Jul 2026, covering the period ending 30 Jun 2026, as reported to the SEC. Data last refreshed 24 Jul 2026. How this is calculated.

Fiscal year ends Dec. Sector medians are approximate S&P 500 benchmarks and update periodically. Checks use broad-market heuristics, so sector norms may differ, and the valuation checks are more cyclical than the quality checks.

Peers

Pharmaceutical Preparations · Pick stocks to compare with SMMT

CompareIntrinsic value
BMRNBiomarin Pharmaceutical Inc.
$58.51+1.77%51
BFRIBiofrontera Inc.
$0.87-6.34%30
BGMBGM Group Ltd.
$9.54-1.90%26
TGTXTG Therapeutics, Inc.
$61.18+5.34%57
RAREUltragenyx Pharmaceutical Inc.
$16.10-4.05%40
IDYAIdeaya Biosciences Inc.
$31.96-2.83%40
MIRMMirum Pharmaceuticals Inc.
$85.00-1.61%30
LEXXLexaria Bioscience Corp.
$3.49-7.43%10

Held by ETFs

SMMT is in 46 US ETFs. The largest of them, with SMMT's weight in each:

Spot a number that looks wrong? Check it in SMMT's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing SMMT

Create a free account and get 14 days of Premium: every stock and every tool.

  • Unlimited stocks
  • Stock screener
  • Portfolio tracker
  • Editable DCF
  • Compare side by side
  • Unlimited alerts

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.

SectorsPrivacyTerms© 2026 Intrinsiqq

Not financial advice. Analytical data for research only.

Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.